
|Articles|January 15, 2004
Fixed-combination drug beneficial in glaucoma therapy
The fixed combination of timolol-dorzolamide (Cosopt, Merck) can be beneficial in glaucoma therapy for several reasons: prescribed in conjunction with a single agent such as a prostaglandin analog, it may achieve a greater reduction in the patient's IOP than the single agent alone, and it can improve compliance, according to two glaucoma experts.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
5